ARTICLE | Company News
ViaCtye Inc., California Institute for Regenerative Medicine endocrine/metabolic news
October 27, 2014 7:00 AM UTC
CIRM awarded ViaCyte an additional $16.6 million to support clinical testing of VC-01. The product is in a Phase I/II trial to treat Type I diabetes. VC-01 comprises ViaCyte's PEC-01 cells, which are human embryonic stem cells (hESCs)-derived pancreatic progenitor cells, encapsulated in ViaCyte's implantable Encaptra delivery system. CIRM awarded $10.1 million in 2012 and $3 million in 2013 to support development of VC-01 (see BioCentury, Nov. 5, 2012 & Feb. 25, 2013). ...